Subscribe
Search
Close this search box.
Subscribe
Search
Close this search box.

Immunology

Biomedical/pharma, Immunology, Oncology

New start-up Trince raises EUR 4 million for innovative technology to produce personalized cancer therapies safer, cheaper, and faster

Confo-dently into the future!

Confo Therapeutics is a rising star in Belgium, featured on several local and international lists of up-and-coming biotechs. The company, launched in 2015 as a spin-off of the Vrije Universiteit Brussel (VUB) and VIB, is now taking the big step from the preclinical to the clinical stage with a GPCR drug for neuropathic pain.

EsoBiotec ready to transform cell therapy cancer treatments

Moderna: from secretive platform company to vaccine superstar

Moderna Therapeutics has never really been a typical biotech. Sure, nowadays it is world famous thanks to its COVID-19 vaccine, which has resulted in an $80 billion market cap and projected sales of $18.4 billion for 2021. But the path to success has not been that of a standard biotech’s journey. Through ups and downs, controversies and triumphs, here’s the fascinating story behind the rise of Moderna and the creation of its COVID-19 vaccine.

Malaria vaccine candidate shows promise for African children

Montis Biosciences Awarded VLAIO Grant to Expand its Pipeline of Novel Immune-Oncology Therapeutics

Trusting gut bacteria: MRM Health develops microbiome treatments for IBD and more

In the last decade, there has been a growing interest in the potential of microbiome-based therapeutics: using gut bacteria as a medication to battle a wide array of diseases. Ghent-based start-up MRM Health is an important innovator in this growing field, building on the expertise of sister company ProDigest and of prominent partners such as VIB and DuPont Nutrition Biosciences. In the coming months, MRM Health is starting clinical trials for a drug candidate for ulcerative colitis, a type of inflammatory bowel disease (IBD).

AgomAb’s journey of growth in regenerative medicine

Ghent-based AgomAb Therapeutics recently raised a Series B of $74 million, the largest round ever for a Belgian biotech in pre-clinical phase. Based on argenx’ technology, the company is developing HGF-mimetic antibodies for regenerative medicine. AgomAb has come a long way since it’s foundation in 2017 and has been pegged by many as one of the future stars of Belgian biotech.

Montis Biosciences appoints René Hoet as Chief Scientific Officer

Leuven, Belgium, 31 March 2021 - MONTIS BIOSCIENCES, a discovery stage biotech company focused on the development of novel immuno-oncology therapeutics targeting the interactions between perivascular macrophages and the tumor vasculature, appoints René Hoet, Ph.D. as its Chief Scientific Officer. Dr Hoet brings extensive experience in antibody drug discovery and development, through his international career in Biotech and Pharma.

Record-breaking pollen levels linked to increased risk of COVID-19

Increased pollen concentrations are correlated with higher rates of COVID-19. Hot on the heels of record-breaking European pollen counts, this comes as bad news for a continent struggling with the ongoing health crisis. The large-scale study, conducted by an international team headed by researchers in Germany, suggested people protect themselves by keeping an eye on pollen forecasts and wearing particle filtering masks this spring.

Saving man’s best friend: Volition blood test allows cheap and easy cancer screenings for dogs

A Belgian invention is revolutionizing cancer diagnostics for dogs by making it possible to screen for two common canine cancers with a simple, low-cost blood test. The innovation was developed by the Belgian subsidiary of Volition, a multinational company listed on the New York stock exchange. The company is also developing human blood tests for use in oncology as well as a number of other diseases including COVID-19.

Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center

Dutch biotech company developing first-in-class T-cell Receptor (TCR) T-cell therapies. Seed investment by Swanbridge Capital and Van Herk Ventures with support from Health~Holland

One year of COVID-19: a look back at 2020 and where we are now

One year on from the emergence of SARS-COV-2 in Wuhan, China, this novel coronavirus continues to devastate the world. Since then, COVID-19 has reached every continent and touched all of our lives. In this article, we take the chance to assess the situation going into 2021 and look back on the first year of the pandemic.

Decades-old discoveries cause paradigm shifts in modern medicine

Complete paradigm shifts in medicine are rare, but there have nevertheless been several major examples in the past hundred years. Treatments and approaches that seemed set in stone one decade can easily seem silly the next, as new information about the disease or underlying biology comes to light. Hindsight grants us clarity, but sometimes the factors that lead us down a particular treatment path can be as arbitrary as a feud between colleagues. Might there be paradigm shifts looming in oncology, neurology and more, triggered by a return to previous treatments?

Newton Biocapital I invests in Perseus Proteomics Inc. in Japan to develop therapeutic antibodies for the treatment of blood cancers

Brussels, Belgium / Tokyo, Japan – 1 December 2020 – Newton Biocapital I (“Newton”), a life sciences investment fund active in Europe and Japan and focused on the treatment and prevention of chronic diseases, has announced its third investment in Japan. Newton invested EUR 1.2 million (JPY 148 million) in Perseus Proteomics Inc. as part of a total round of EUR 8.1 million. With this investment, Perseus Proteomics will continue its research and development of PPMX-T003 - a key growth driver antibody - and other antibodies in the pipeline.